THE PRESENT INVENTION RELATES TO THE JANUS KINASE (JAK) INHIBITORS 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANENITRILE OR 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]HEPTANENITRILE, AS WELL AS ITS COMPOSITIONS AND METHODS OF USE, WHICH IS USEFUL IN THE TREATMENT OF JAK-ASSOCIATED DISEASES INCLUDING, FOR EXAMPLE, INFLAMMATORY AND AUTOIMMUNE DISORDERS, SKIN DISORDERS, CANCER, AND OTHER DISEASES.